Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases. The discontinuation will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results